Breakthroughs in Cancer Research and Treatment at The University of Texas M. D. Anderson Cancer Center

Strategic Insights -

Researchers at The University of Texas M. D. Anderson Cancer Center have made significant advancements in understanding and treating various types of cancer. Recent studies have shed light on the potential of a genetic biomarker for selecting among chemotherapy choices for non-small-cell lung cancer, the benefits of exercise for breast cancer survivors, and the introduction of proton therapy at the Proton Therapy Center.

The research highlighted a genetic biomarker, NPRL2, which shows potential predictive value for care in non-small-cell lung cancer. Patients with non-small-cell lung cancer lacking an active NPRL2 gene may not respond well to cisplatin, a commonly used chemotherapy drug. The study's findings suggest that NPRL2 could serve as a biomarker for selecting among chemotherapy choices, as well as a therapeutic target for restoring the effectiveness of cisplatin in treating resistant forms of the disease.

Another study emphasized the importance of exercise for breast cancer survivors, demonstrating that it can decrease pain and improve physical well-being. Researchers taught breast cancer survivors how to incorporate short periods of moderate exercise into their daily routines, which resulted in a significant increase in physical activity and a notable reduction in pain and limitations due to physical health problems.

Recently, the Proton Therapy Center at The University of Texas M. D. Anderson Cancer Center has begun treating patients, offering the most advanced innovation in radiation therapy. Proton therapy is the most precise form of radiation treatment available for some tumors, minimizing harm to surrounding tissues and optimizing treatment of the tumor.

Key Takeaways:

  • A genetic biomarker, NPRL2, shows potential predictive value for care in non-small-cell lung cancer, suggesting that patients with a lack of active NPRL2 gene may not respond well to cisplatin.
  • Exercise can significantly decrease pain and improve physical well-being in breast cancer survivors by increasing physical activity and reducing limits due to physical health problems.
  • The Proton Therapy Center at M. D. Anderson Cancer Center offers the most advanced innovation in radiation therapy, providing precise treatment with minimal harm to surrounding tissues.
  • Proton therapy has been used to treat over 40,000 patients worldwide and is expected to accommodate 3,500 patients per year at M. D. Anderson's facility, making it the largest in the world.
  • Researchers continue to study the mechanisms by which the NPRL2 gene kills cancer cells in combination with cisplatin and its normal role in DNA damage repair and apoptosis.
  • Partner organizations, including the Kelsey Research Foundation, the Houston chapter of the Sisters' Network, and The Rose, played a crucial role in recruiting participants for the exercise intervention study.

Statistics:

  • 40 different lines of non-small-cell lung cancer were analyzed for NPRL2 expression, with 21 lines expressing the gene and 15 of those being sensitive to cisplatin.
  • 19 lines had little or no expression of NPRL2, with 15 of those being cisplatin-resistant.
  • Laboratory experiments showed that NPRL2 expression with cisplatin drastically limited cancer cell proliferation and increased programmed cell death (apoptosis) of cancer cells by 2 to 3 fold.
  • Mice treated with NPRL2-nanoparticles and cisplatin showed a 90% reduction in tumor volume compared to those treated only with cisplatin or a combination of cisplatin and control delivery systems.
  • Participants who received lifestyle intervention training showed significant physical improvement, walking an average of 100 feet further than their control group peers.
  • Over 40,000 patients have received proton therapy treatment worldwide.

Sources:

  • Basen-Engquist, K. (2006). The Active for Life after Breast Cancer Study. Patient Education and Counseling.
  • Ji, L. (2006). NPRL2 has potential predictive value for care in non-small-cell lung cancer. Cancer Research.
  • Cox, J. D. (2006). Proton Therapy Center at M. D. Anderson Cancer Center. Health & Medicine Week via NewsRx.com.